ONO PHARMACEUTICAL CO.,LTD. (4528.T) Financial Statements

Income statement

Metric	TTM	2026	2025	2024	2023
Revenue
Total Revenue	509.3B	515.8B	486.9B	502.7B	447.2B
Cost of Revenue	37.0B	141.7B	147.9B	127.1B	110.1B
Gross Profit	90.5B	374.1B	338.9B	375.5B	337.1B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	31.1B	123.7B	125.7B	100.3B	89.5B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	1.3B	12.0B	4.7B	4.3B	11.1B
Total Operating Expenses	32.4B	135.7B	130.4B	104.6B	100.6B
Cost and Expenses	432.1B	423.5B	427.1B	342.7B	305.2B
Operating Income (EBIT)	77.3B	92.2B	59.7B	159.9B	142.0B
Non-Operating
Interest Income	1.4B	4.0B	4.8B	4.0B	2.5B
Interest Expense	773.0M	3.5B	5.3B	229.0M	913.0M
Net Interest Income	655.0M	417.0M	(544.0M)	3.8B	1.6B
Other Non-Op Income/Expense	113.0M	913.0M	1.1B	1.2B	734.0M
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	22.6B	92.7B	59.3B	163.7B	143.5B
Income Tax Expense	5.0B	22.7B	9.2B	35.7B	30.6B
Bottom Line
Net Income	62.4B	69.8B	50.0B	128.0B	112.7B
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	62.5B	69.9B	50.2B	128.0B	112.9B
Per Share
Basic EPS	¥133	¥148	¥107	¥267	¥231
Diluted EPS	¥133	¥148	¥106	¥267	¥231
Revenue Per Share	¥1,084	¥1,098	¥1,037	¥1,047	¥916
Shares
Basic Shares Outstanding	469.8M	469.9M	469.7M	480.0M	488.3M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	31.2B	130.0B	86.6B	178.1B	159.4B
D&A	9.2B	37.8B	26.9B	18.1B	17.5B
EBIT	77.3B	92.2B	59.7B	159.9B	142.0B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026